The webinar provided background information on various call topics and on support available for both UK and European organisations in how to apply for funding and search for partners. KTN hosted this event on behalf of Innovate UK and was delivered by Samana Brannigan, National Contact Point for Health, and Stephen Alexander, National Contact Point for Legal and Financial Issues. The webinar gave an overview of H2020 Health Call topics, and support available for UK organisations in how to apply for funding, as well as information on Brexit and the continuation of UK participation in H2020. This enabled attendees to gain an insight into the benefits of participating, guidelines for preparing a project outline and the support and collaboration tools available. In summary, the webinar covered: - Open and Forthcoming Health Call Topics - Support for UK Organisations - UK participation in Horizon 2020 Find out more about the Health Special Interest Group at https://ktn-uk.co.uk/interests/health

1. H2020 Briefing Webinar on the 2020
Infectious Disease Calls
Samana Brannigan –NCP Health

2. Content:
1. NCP Role
2. What is H2020?
3. How to apply
4. Priority 3 – Infectious diseases and improving global health
5. Useful links

3. Network of National Contact Points (NCPs)
Main structure to provide guidance, practical information and
assistance on all aspects of participation in Horizon 2020.
20% 80%
NCP-rules@innovateuk.ukri.org

4. What is Horizon 2020?
- EUR 80 billion available 2014-2020 – it’s large scale collaborative research and innovation

5. The “way in”
FIND
a call
FIND
partners
SUBMIT
proposal
DELIVER
project
Today’s webinar

6. Priority 3 – Infectious diseases and improving global
health -
SC1-BHC-17-2020 Global Alliance fro Chronic Diseases (GACD) Prevention
and /or early diagnosis of cancer
SC1-BHC-20A-2020 Pre-commercial procurement (PCP) for integrated care
solutions
SC1-BHC-20B-2020 Public procurement of innovative solutions (PPI) for
diagnostics for infectious diseases
SC1-BHC-34-2020 New approaches for clinical management and prevention
of resistant bacteria infections in high prevalence settings
SC1-BHC-35-2020 Creation of a European wide sustainable network for
harmonised large-scale clinical research studies for infectious diseases
All Calls- Open Closes- 7th April 2020

7. Priority 3
Aim
• Fighting infectious diseases and the growing threat of antimicrobial
resistance;
• Addressing the needs of the most vulnerable and the global increase
in chronic diseases
Focus
Emerging infectious diseases, poverty and neglected diseases, stratified
host-directed approaches to communicable diseases, maternal and
child health, global collaboration on non-communicable diseases
(cohorts, brain research, hypertension, diabetes, cancer)

8. POLICY DRIVERS and SUPPORT FOR:
GLOBAL
RESEARCH
COLLABORATION
FOR INFECTIOUS
DISEASE
PREPAREDNESS
European One
Health Action Plan
against
Antimicrobial
Resistance
European &
Developing
Countries Clinical
Trials Partnership
Global
Alliance for
Chronic
Diseases
Global Action
Plan on
antimicrobial
resistance

9. SC1-BHC-17-2020: Global Alliance for Chronic Diseases (GACD) -
Prevention and/or early diagnosis of cancer
Scope
• Implementation research for prevention and/or early diagnosis of
cancer on in LMIC and/or in vulnerable populations in HIC
• Interventions with promising or proven effectiveness (including cost-
effectiveness) for the respective population groups
• A limited validation period can be envisaged, however, the core of the
research activities should focus on their implementation in real-life
settings.
• The proposed interventions should gender-responsive.

10. Proposal Focus
• Lead to better understanding of key barriers and facilitators at local,
national and international level that affect the prevention and/or early
diagnosis of cancer
• Include health economics assessments as an integral part of the proposal
• Propose a pathway to embed the intervention into local, regional or
national health policy and practice
• Include policy makers and local authorities (possibly part of the
consortium) where relevant from the beginning of the project, to ensure
sustainability of the intervention after project ends
(community groups, patient groups, formal and informal carers and any
other group)

11. Expected impact
• Advance local, regional or national cancer prevention and/or early
diagnostic health policies
• Inform health service providers, policy and decision makers on
effective scaling up of cancer interventions at local, regional, and
national levels
• Provide pathway to cancer care for the patients diagnosed with
cancer
Research and innovation action
Total Budget: 20 M€ – 1-3 M€/proposal

12. SC1-BHC-20A-2020 Pre-commercial procurement
(PCP) for integrated care solutions
Scope
• Procurers with similar procurement needs that want to procure
together the development of innovative integrated care solutions to
modernize public services
• Solution can include organisational solutions, personal-health and
self-care solutions, professional care solutions, ICT-based solutions,
among other.
• Open both to proposals requiring improvements mainly based on one
specific solution/technology field, as well as to proposals requiring
end-to-end solutions that need combinations of different innovative
solutions from the healthcare point of view.

13. Proposal Focus
• Demonstrate sustainability of the action beyond the life of the
project.
• Include cooperation with policy makers to reinforce the national
policy frameworks and mobilise substantial additional national
budgets for PCP and PPI, collaborating with respective EU funded
projects in the area
• Awareness raising, technical assistance and/or capacity building to
other procurers beyond the project to mainstream PCP
implementation
• Remove obstacles for introducing the innovative solutions to be
procured into the market.

14. Expected impact
• Reduced fragmentation of demand for innovative solutions in the
area of integrated care;
• Increased opportunities for wide market uptake and economies of
scale for the supply through joint specifications, wide publication of
results and where relevant contribution to standardisation, regulation
or certification
Pre-Commercial Procurement
Total Budget- 25 M€- up to 5-6 million EUR/proposal (up to 90% of
total budget)

15. SC1-BHC-20B-2020 Public procurement of innovative
solutions (PPI) for diagnostics for infectious diseases
Scope
• Implementation of rapid diagnostic tools for infectious diseases in
clinical practice.
• Proposals should be driven by clearly identified procurement needs of
the participating organisations.
• In order to ensure compatibility and interoperability between
infectious disease diagnostics and avoid technical/technology
standardisation issues, public health procurers should also develop
specifications that are applicable for EU-wide deployment of the
innovative diagnostics.

16. Proposal Focus
• Applications should be driven by public and/or private procurers from
each participating country (at national, regional or local level) that
have responsibilities and budget control in the relevant area of supply
of health and care services.
• Demonstrate the applicability of the ‘Most Economically
Advantageous Tendering’ approach in cross-border collaboration of
public procurers in the EU, defining specific outcome criteria of
importance for patients well-being
• Take into account overall economic and societal benefits, and sex and
gender differences

17. Expected impact
• Contribute to the EU One Health Action Plan on Antimicrobial
Resistance
• Create new opportunities for market uptake and economies of scale
for the supply side of rapid diagnostics in the area of respiratory tract
infections across the EU
Public Procurement of Innovative solutions
Total Budget 25€M– 3 to 5 million EUR/proposal (35% of the total
budget)

18. SC1-BHC-34-2020 New approaches for clinical management and
prevention of resistant bacteria infections in high prevalence
settings
Scope
• Identification of best practices, and the development and validation
of interventions, infection prevention and clinical management plans
for dealing with resistant bacterial infections in high prevalence
settings.
• Take into account the variety and capacities of local health
care/nosocomial infrastructures, and the trends of resistance patterns
on local, national and international level.
• Lead to management plans.

19. Expected impact
• Availability of tested cost effective models for prevention and
treatment of bacterial infections in health care settings with high
prevalence levels of resistant infections.
• Reduced spread of resistant hospital acquired infections in these
settings.
• Knowledge that can be of use for other countries around the globe,
including low and middle income countries, benefitting their local
population
Research and innovation action
Total Budget: 25 M€ – 10-15 M€/proposal

20. SC1-BHC-35-2020 Creation of a European wide sustainable
network for harmonised large-scale clinical research studies for
infectious diseases
Scope
• Proposals should set up a European-wide multidisciplinary network
able to provide a platform for a rapid response in the conduct of
clinical studies in relation to any severe infection.
• Include initial clinical studies to be performed
• Criteria and processes for including further clinical studies in the
project should be clearly described. This
• Should include provisions for flexibility in case of new scientific
developments

21. Expected impact
• Reduced cost and time through efficiently implemented clinical trials
for diagnosis, prevention and treatment of infections.
• Create and strengthen the operational capacity and the
infrastructures for providing real-time evidence for optimal medical
intervention and practice in infectious diseases.
• Contribute to existing EU policies on vaccines and AMR
Research and innovation action
Budget- 30 M€ – 25-30 M€/proposal

22. Useful Links
Latest version of the Health Work Programme:
https://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-
2020/main/h2020-wp1820-health_en.pdf
Participant portal – one–stop shop
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home
Information on: Call topics/NCPs/Expert registration/Project officers' list for
questions/FAQs/Rules for participation

23. Thank you for your time and attention!
NCP-health@innovateuk.ukri.org
07557205496

24. UK Participation in H2020
Stephen Alexander
Legal & Financial NCP
H2020UK National Contact Points
National Contact Points are an Innovate
UK resource to assist UK Business to
engage with EU Research & Innovation
Funding opportunities
Fact Pack v1

25. • UK-based individuals and organisations would remain eligible to bid for
funding, participate in and lead consortia including calls in 2019 and 2020
on the same basis as now
• If an agreement is reached, projects approved during this period will be
able to continue with an uninterrupted flow of EU funding
• But, ‘nothing is agreed until everything is agreed’
• Where do we stand if no-deal?
Withdrawal Agreement: Horizon 2020
“Following withdrawal from the Union, the UK will continue to
participate in the Union programmes financed by the MFF 2014-
2020 until their closure.”

26. UK Eligibility to participate in H2020 post Brexit (no deal)
• Free to participate as a non-EU country, a ‘third country’ across
most of H2020
• Can continue to coordinate projects and distribute EU funds
• Not automatically eligible for EU funding
• Unless essential for action
• Or provision made in workprogramme/call
• Some obligations under the GA will no longer apply
• UK not eligible for some actions:
• Monobeneficiary - ERC, MSCA
• Some Space and Security projects
• Some multi-beneficiary – FTI, SMEi
• For most ongoing projects and new projects, funding will be
replaced by the Treasury underwrite guarantee

27. • The UK Government has committed to underwrite Horizon 2020 funding for all successful
UK bids submitted before exit, even if they are notified of their success after exit, for the
lifetime of the projects
• UK Research and Innovation (UKRI) will also manage the independent assessment of UK
applications to ERC, MSCA and SMEi grants that have been submitted before Brexit, if they
are not assessed by the European Commission.
• This will support UK participants to continue to take part in Horizon 2020 projects in no deal
scenario, subject to continued eligibility.
Underwrite Guarantee and extension funding
• Guarantees EU Funding for UK researchers beyond the date
the UK leaves the EU
• Through the extension to the guarantee, the government has
committed to fund UK participants’ funding in all Horizon 2020
calls open to third country participants from the date of exit.
HMT Underwrite Guarantee

28. Current ongoing projects
• Project delivery should continue as per the grant agreement
• Participation as a third country entity
• UK coordinators will remain eligible to coordinate and manage EU
funds
• Funded by EU to end October, UK underwrite thereafter
• If the project is only open to EU and Associated countries – the
grant may be terminated by the EU.
• If viable as a standalone project, the underwrite will still apply
• If non-viable – funding will be available to cover the costs
associated with project closure
• If the project has the minimum number of participants and UK
status means the project is ineligible – it may be terminated
• The underwrite will apply as above – viable/non-viable

29. New bids submitted before exit
• Proposals will be assessed by EU if the action is open to third
countries
• If successful, you will participate as a third country but with UK
funding from the start of the project
• However, if the project is only open to EU and Associated
countries - It may not be evaluated
• You will be able to re-submit to UKRI for independent assessment
• If successful, you will receive Government ‘in-flight’ funding for
the lifetime of the project
• The grant agreement will be with UKRI under standard UK T&Cs

30. Applying after exit
• Most calls will be open to third country participation – but check
with your NCP if necessary
• The project will continue to have an EU grant agreement but with
funding via UK extended underwrite
• But, UK not eligible for some actions:
• Some monobeneficiary – in ERC, MSCA
• Some Space and Security projects
• Some multi-beneficiary – EIC Accelerator (formerly SMEi)

31. Delivery of government funding
• The Treasury guarantee will be delivered by UK Research and
Innovation (UKRI)
• Grant holders who have registered on the UKRI portal will be
contacted to set out the steps to access guarantee funding
• UKRI will require evidence of your grant or grant offer, i.e.:
• Proof of grant
• Proof of grant amount
• Proof of any payments already received
• Any financial statements submitted since last payment
• Proof of project costs incurred since last payment
• Information on types of acceptable evidence will be available on
the UKRI website
• Do NOT submit documents until requested by UKRI

32. Delivery of government funding – ‘onboarding’
• Once documents are submitted, your grant will be ‘onboarded’ to
existing UKRI grant management systems
• Je-S for academia, quarterly payments
• IFS for industry, payments on a claims basis, in arrears
• You will sign a contract with UKRI - in most cases this will be
alongside your existing EU grant agreement
• Guarantee payments will be in pounds Sterling (£)
• For ‘In-flight’ projects (those independently assessed by UKRI) –
there will be a single grant agreement with under UKRI T&Cs

33. What happens at exit – ‘EU side’?
(current ongoing projects)
• In theory, TBC…
• Amendment to project grant agreement
• Triggered by Commission
• Introduce article-9 (implementation of action tasks by beneficiaries
not receiving EU funding)
• Amend maximum project grant amount
• Interim/break report (technical & financial) to end of
October…
• Agree financial balance – payment or recovery from UK
participant
• UK partner still a signatory to the GA and bound by most
obligations
• Some projects that fail to maintain eligibility may be
terminated

34. Underwrite portal
• The portal is designed to ensure that UKRI has the information about projects
and participants in order to underwrite guarantee payments if required.
• The website is for UK participants who are in receipt of Horizon 2020 funding
(including EDCTP2, EMPIR, EIT-KICs). It is also for Euratom R&T and ongoing
Framework Programme 7 projects.
• Register your project on the portal at: https://apply-for-innovation-
funding.service.gov.uk/eu-grant/overview
• Update sent to all registered beneficiaries on 10th September
– Confirming the documentary evidence of your grant that will have to be submitted
(proof of grant, grant amount, payments received, claims submitted, costs incurred
since last payment)
– Useful to start gathering this – but do not submit until requested

35. • UK participation in Horizon 2020 after Brexit (October 9th)
https://www.gov.uk/government/publications/uk-
participation-in-horizon-2020-uk-government-overview/uk-
participation-in-horizon-2020-after-brexit
• UKRI & EU Exit - underwrite
https://www.ukri.org/research/international/ukri-eu-exit/
N.B. Further details will be released on the UKRI website
UK Government guidance and how to prepare

36. Contact
For further information on H2020
and on the rules for participation:
Stephen Alexander
Email: NCP-RULES@innovateuk.gov.uk
Phone: 07771-722217

37. Accelerating innovative drug discovery
Connecting the UK drug discovery community
Transforming ideas into better medicines
for patients, faster

38. National facility connecting the UK community
to accelerate innovative drug discovery
Medicines Discovery Catapult
WHO WHY HOW WHAT WHERE WORK WITH US
• Independent not-for-profit
• Part of the UK’s Catapult network
• Helping to deliver the UK’s Industrial Strategy
• Funded by Innovate UK, part of UK Research and Innovation,
reporting to the Department for Business, Energy & Industrial
Strategy

39. WHO WHY HOW WHAT WHERE WORK WITH US
The shape of drug discovery is changing
Drug discovery must be faster and cheaper without
compromising patient safety
The industry needs new scientific approaches to
influence and enable better decision making
1. Paul, S.M. et al. (2010) How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 9(3), 203-214.
2. Deloitte (2017) A new future for R&D? Measuring the return from pharmaceutical innovation 2017.
9/10 potential drugs fail
between phase 1 trials and
regulatory approval
13.5 YEARS FOR 1 MEDICINE1
~£1.2 BILLION2
UNPREDICTABLE
FEW SUCCESSES
TIME CONSUMING AND EXPENSIVE

40. SMEs are the agile risk-taking testers of new ideas, for innovation, discovery and
validation of new drugs and technologies
SMEs account for more than 90% of our UK life sciences community1
But 42% of biotech SMEs have less than 5 employees2 and struggle to access:
WHO WHY HOW WHAT WHERE WORK WITH US
The industry is increasingly reliant on SMEs to innovate
Funding Expertise Technology
1. HMG (2016) Strength and opportunity 2016: The landscape of the medical and biopharmaceutical sectors in the UK.
2. BIS (2015) Strength and opportunity 2015: The landscape of the medical technology and biopharmaceutical sectors in the UK.

41. • Industrialise, and drive the adoption of new scientific tools and modern techniques for discovering medicines
• Target specific industry-led challenges that limit today’s discovery process
• Deploy scarce expertise and know-how to connect a fragmented community and leverage current UK infrastructure
• Support the UK life sciences industry, SMEs and innovators to deliver growth for the UK life sciences economy
The enabling products and services that we diffuse into the sector will help UK SMEs fill their pipelines
with targeted medicines tested in patients, faster​
WHO WHY HOW WHAT WHERE WORK WITH US
Our aims
Our vision

42. Providing unique
scientific capabilities
Acting as a gateway
to UK resources
& expertise
By providing access to technologies and expertise not readily accessible we will support UK SMEs to
drive the development and widespread use of new approaches for the discovery of new medicines
WHO WHY HOW WHAT WHERE WORK WITH US
We are focussed on enabling UK drug discovery

43. We will not
• Compete with pharmaceutical or service companies
• Perform independent medicines discovery
• Replicate readily available UK infrastructure
We will prioritise and exemplify our efforts
• In areas where UK science is perceived as ‘strong’
• In areas where SME needs are not met by others
• On development and promotion of cross-cutting discovery approaches
WHO WHY HOW WHAT WHERE WORK WITH US
We are focussed on enabling UK drug discovery

44. DISCOVERY SCIENCE
& TECHNOLOGY
INFORMATICS SAMPLES & DATA VIRTUAL R&D SYNDICATES
WHO WHY HOW WHAT WHERE WORK WITH US
Our unique capabilities
Designed to address the needs of our UK drug discovery community and change the shape of R&D:
BETTER DATA FASTER
ACCESS TO UK RESOURCES & EXPERTISE

45. Establishing patient-relevant testing models and
new technologies to advance drug discovery
Discovery Science & Technology
WHO WHY HOW WHAT WHERE WORK WITH US

46. Discovering and connecting data to build new
algorithms, AI and machine learning approaches
Informatics
WHO WHY HOW WHAT WHERE WORK WITH US
In silico TARGET
VALIDATION USING
REAL WORLD DATA
DRUG REPURPOSING
DRUGGABILITY
NOVEL DRUG
COMBINATIONS
EFFICACY AND
SAFETY ANALYSIS
UNDERSTANDING
CHEMICAL SPACE

47. Brokering easier access to consented patient
data and samples
Samples & Data
WHO WHY HOW WHAT WHERE WORK WITH US
Working with key organisations we are supporting access to
consented tissues & data
DIRECTORIES
RESEARCH SERVICES
PROCUREMENT SERVICES

48. Leveraging the UK’s renowned leadership
in drug discovery – a modern approach to R&D
Virtual R&D
Our VR&D platform uses a unique national network of up-to-date
industry-skilled consultants and service providers to deliver three
essential elements
WHO WHY HOW WHAT WHERE WORK WITH US
EXPERT ADVICE SERVICE
UK CAPABILITY MAP
VIRTUAL PROGRAMME
MANAGEMENT

49. Syndicates
WHO WHY HOW WHAT WHERE WORK WITH US
Drive a disease-focussed, patient-centric research agenda
Enabling patient-centred drug discovery
– a collective approach to R&D
Syndicates provide a new model for collaborative
research centred around patients needs
Syndicates will:
Accelerate the translation of research to the clinic
De-risk new promising assets and drive commercialisation
Create new and more efficient funding and investment models

50. WHO WHY HOW WHAT WHERE WORK WITH US
National facility and laboratory
Our office and laboratories are based at Alderley Park in Cheshire
Providing UK SMEs with access to the UK’s second largest life sciences cluster and unrivalled opportunities

51. WHO WHY HOW WHAT WHERE WORK WITH US
We work with our partners in a range of different models
Shared risk and reward
Joint grant applications for
collaborative R&D funding
Contracted fee-for-service projects
Signposting and connecting

52. Visit our website for our latest partnerships and
funding opportunities.
Get in touch for more information, expert guidance,
strategic consultancy and access to our technology.
Or to discuss a potential project or service.
WHO WHY HOW WHAT WHERE WORK WITH US
Get in touch now
md.catapult.org.uk
@meddisccat
info@md.catapult.org.uk
01625 238734